AR blockers synergized with cytarabine in vitro, reducing the viability of AML cells; the combination index (CI) was 0.87 and 0.81 for enzalutamide and darolutamide, respectively (CI < 1 indicates synergism). Here, AR is linked to acute myeloid leukemia.